Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Glen Burnie, Maryland Clinical Trials

A listing of Glen Burnie, Maryland clinical trials actively recruiting patient volunteers.

RESULTS

Found (19) clinical trials

Impact of Guided Care With the Vectra DA Multi-biomarker Disease Activity (MBDA) Blood Test

Nine months multi-center prospective, site randomized, two arm trial to evaluate the effect of MBDA score-guided care on disease activity and medical costs. To investigate whether treatment decisions guided by MBDA scores result in reduced disease activity and overall medical cost among patients with RA relative to usual care (UC).

Phase N/A

0.0 miles

Learn More »

Evaluation of the Safety Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

This is a phase 1, 2 part, double-blind (sponsor-unblinded), randomized, placebo-controlled, FTIH study in a combined single-ascending and multiple-ascending dose to assess the safety, tolerability, and PK/pharmacodynamics (PD) attributes of GSK3732394 in healthy subjects. The data gathered in this study will further enable clinical development of GSK3732394 in HIV-infected subjects. ...

Phase

4.29 miles

Learn More »

A Study of a Single Subcutaneous Dose of JNJ-26366821 in Healthy Participants

The purpose of this study is to evaluate the safety and tolerability of a single subcutaneous (SC) dose of JNJ-26366821.

Phase

4.29 miles

Learn More »

A Study to Evaluate the Safety Pharmacokinetics Pharmacodynamics and Immunogenicity of PRV-3279 in Healthy Subjects

PRV-3279-1b is a Phase 1b, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of PRV-3279 in Healthy Subjects. Eligible subjects include healthy male or female adults, 18 to 50 years of age. Each subject will receive the assigned treatment over 29 days followed ...

Phase

4.29 miles

Learn More »

Medical Management of Sleep Disturbance During Opioid Tapering

This study will evaluate whether a dual orexin-receptor antagonist approved by the FDA for sleep disturbance, suvorexant (SUVO; Belsomra), will increase total sleep time in patients with opioid use disorder (OUD) undergoing supervised withdrawal. This study is designed as a dose-finding study of SUVO compared to placebo. Briefly, OUD patients ...

Phase

8.2 miles

Learn More »

Safety and Tolerability Study of Nivolumab and Cabiralizumab for Resectable Biliary Tract Cancer

The purposed of this research is to study the safety and clinical activity of the combination of nivolumab and cabiralizumab in people with resectable biliary tract cancers (BTC).

Phase

8.24 miles

Learn More »

Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma

PRIMARY OBJECTIVE To determine safety of each of the following study agents, anti-GITR, IDO1 inhibitor, and ipilimumab, in combination with nivolumab (BMS-936558) flat dose in patients with first recurrence of GBM. SECONDARY OBJECTIVES To estimate toxicity To estimate progression-free survival To estimate overall survival To evaluate pain for patients undergoing ...

Phase

8.82 miles

Learn More »

Adapted ACHIEVE Curriculum for Community Mental Health Settings

Prevalence of obesity is significantly elevated and a leading cause of preventable death in people with serious mental illness (SMI) through its effects on other cardiovascular disease (CVD) risk factors and CVD. Behavioral interventions targeting changes in diet and exercise need to be tailored to the needs of people with ...

Phase N/A

8.82 miles

Learn More »

Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma

This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo. The primary objective of this study is to evaluate the effect of cabozantinib in combination with nivolumab and ipilimumab ("triplet") on the duration ...

Phase

8.82 miles

Learn More »

A Study To Investigate The Pharmacokinetics Safety And Tolerability Of Subcutaneous Ocrelizumab Administration In Patients With Multiple Sclerosis

This study will evaluate the pharmacokinetics, safety and tolerability, and immunogenicity of ocrelizumab administered subcutaneously to patients with multiple sclerosis (MS).

Phase

8.82 miles

Learn More »